Vistagen Therapeutics (NASDAQ:VTGN) had its target price decreased by equities researchers at Chardan Capital from $30.00 to $22.00 in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock.
Vistagen Therapeutics (VTGN) opened at $1.16 on Thursday. Vistagen Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.15. The firm has a market cap of $26.00, a PE ratio of -0.79 and a beta of -1.31. The company has a debt-to-equity ratio of -0.01, a current ratio of 1.23 and a quick ratio of 1.23.
Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.05). equities analysts expect that Vistagen Therapeutics will post -1.99 earnings per share for the current year.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.